Brief: Black Diamond Therapeutics Announces First Patient Dosed In Phase 1 Study Of BDTX-1535
18/04/2022 12:08
April 18 (Reuters) - Black Diamond Therapeutics Inc
BDTX.O :
* BLACK DIAMOND THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED
IN
PHASE 1 STUDY OF BDTX-1535, A MASTERKEY INHIBITOR OF EGFR FOR
THE TREATMENT OF GLIOBLASTOMA AND NON-SMALL CELL LUNG CANCER
Source text for Eikon: ID:nGNX60BFXm
Further company coverage: BDTX.O
Recent news on Black Diamond Therapeutics
See all newsBlack Diamond Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Black Diamond Therapeutics Q2 net loss narrows year over year
Black Diamond Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Black Diamond Therapeutics Q4 net loss narrows, full-year profit turns positive
U.S. STOCKS ON THE MOVE-Spirit AeroSystems, Boeing, Roblox